{"docid":"VWS-WOO-08-1018495","collapsed":true,"count":1,"unchecked":0,"snapshots_total":9,"versions":[{"archive_id":"6f0d25d4-6f9f-4d98-966a-a9a5b71f11f4","bestandsnaam":"VWS-WOO-08-1018495.pdf","created_date":"2026-06-22 02:48:15","last_seen":"2026-06-22 02:48:15","from_file":"VWS-WOO-3395155-1032354-PDO-1f026c98-53dc-609a-93c3-65673e0af118.zip","bron":"archieven_files\\VWS-WOO-3395155-1032354-PDO-1f026c98-53dc-609a-93c3-65673e0af118.zip","snippet":"1018495\nVERTROUWELLIK\nIndicatiestelling COVID-19 hyperimmuun immuunglobuline alsprofylaxeentherapie bij\nCOVID-19\nAanleiding\nSARS-CoV-2 iseen nieuw infectieus respiratoirvirus. Hoewel deziekte, COVID-1","digest":"0b2a25e763b6","dupes":9,"date_to":"2026-06-22 02:48:15","date_from":"2025-02-18 12:18:07","unchecked":false}],"raw":[{"archive_id":"6f0d25d4-6f9f-4d98-966a-a9a5b71f11f4","bestandsnaam":"VWS-WOO-08-1018495.pdf","created_date":"2026-06-22 02:48:15","last_seen":"2026-06-22 02:48:15","from_file":"VWS-WOO-3395155-1032354-PDO-1f026c98-53dc-609a-93c3-65673e0af118.zip","bron":"archieven_files\\VWS-WOO-3395155-1032354-PDO-1f026c98-53dc-609a-93c3-65673e0af118.zip","snippet":"1018495\nVERTROUWELLIK\nIndicatiestelling COVID-19 hyperimmuun immuunglobuline alsprofylaxeentherapie bij\nCOVID-19\nAanleiding\nSARS-CoV-2 iseen nieuw infectieus respiratoirvirus. Hoewel deziekte, COVID-1","digest":"0b2a25e763b6"},{"archive_id":"0359594b-9921-4289-b220-1668506671b7","bestandsnaam":"VWS-WOO-08-1018495.pdf","created_date":"2025-11-21 15:41:07","last_seen":"2026-06-22 01:47:03","from_file":"VWS-WOO-3395155-1032354-PDO-1f026c98-53dc-609a-93c3-65673e0af118.1.zip","bron":"archieven_files\\VWS-WOO-3395155-1032354-PDO-1f026c98-53dc-609a-93c3-65673e0af118.1.zip","snippet":"1018495\nVERTROUWELLIK\nIndicatiestelling COVID-19 hyperimmuun immuunglobuline alsprofylaxeentherapie bij\nCOVID-19\nAanleiding\nSARS-CoV-2 iseen nieuw infectieus respiratoirvirus. Hoewel deziekte, COVID-1","digest":"0b2a25e763b6"},{"archive_id":"a8f3e24a-0dd2-401a-9c77-7642440dc14c","bestandsnaam":"VWS-WOO-08-1018495.pdf","created_date":"2025-11-21 15:38:42","last_seen":"2025-11-21 15:38:42","from_file":"VWS-WOO-3395155-1032354-PDO-1f0a50fa-40da-605c-8681-b52ef042b7e3.zip","bron":"archieven_files\\VWS-WOO-3395155-1032354-PDO-1f0a50fa-40da-605c-8681-b52ef042b7e3.zip","snippet":"1018495\nVERTROUWELLIK\nIndicatiestelling COVID-19 hyperimmuun immuunglobuline alsprofylaxeentherapie bij\nCOVID-19\nAanleiding\nSARS-CoV-2 iseen nieuw infectieus respiratoirvirus. Hoewel deziekte, COVID-1","digest":"0b2a25e763b6"},{"archive_id":"folder_import_18061_3117f6b56b895fff8cbca5f1bb491f2d","bestandsnaam":"VWS-WOO-08-1018495.pdf","created_date":"2025-09-07 17:20:17","last_seen":"2025-09-07 17:20:17","from_file":"folder_import","bron":"/volume3/websites/openrijksoverheid/documenten_files/VWS-WOO-08-1018495.pdf","snippet":"1018495\nVERTROUWELLIK\nIndicatiestelling COVID-19 hyperimmuun immuunglobuline alsprofylaxeentherapie bij\nCOVID-19\nAanleiding\nSARS-CoV-2 iseen nieuw infectieus respiratoirvirus. Hoewel deziekte, COVID-1","digest":"0b2a25e763b6"},{"archive_id":"VWS-WOO-3395155-1032354-PDO-1f026c98-53dc-609a-93c3-65673e0af118.zip_3444","bestandsnaam":"VWS-WOO-08-1018495.pdf","created_date":"2025-09-04 16:57:59","last_seen":"2025-11-21 13:47:41","from_file":"VWS-WOO-3395155-1032354-PDO-1f026c98-53dc-609a-93c3-65673e0af118.1.zip","bron":"../../archieven_files/VWS-WOO-3395155-1032354-PDO-1f026c98-53dc-609a-93c3-65673e0af118.1.zip","snippet":"1018495\nVERTROUWELLIK\nIndicatiestelling COVID-19 hyperimmuun immuunglobuline alsprofylaxeentherapie bij\nCOVID-19\nAanleiding\nSARS-CoV-2 iseen nieuw infectieus respiratoirvirus. Hoewel deziekte, COVID-1","digest":"0b2a25e763b6"},{"archive_id":"319985","bestandsnaam":"VWS-WOO-08-1018495.pdf","created_date":"2025-03-18 09:30:24","last_seen":"2025-03-18 09:30:24","from_file":"2024.075-VWS-WOO-3395155-1032354-PDO.zip","bron":"Z:\\ARCHIEF WOO Documenten\\archieven_files\\2024.075-VWS-WOO-3395155-1032354-PDO.zip","snippet":"1018495\nVERTROUWELLIK\nIndicatiestelling COVID-19 hyperimmuun immuunglobuline alsprofylaxeentherapie bij\nCOVID-19\nAanleiding\nSARS-CoV-2 iseen nieuw infectieus respiratoirvirus. Hoewel deziekte, COVID-1","digest":"0b2a25e763b6"},{"archive_id":"232539","bestandsnaam":"VWS-WOO-08-1018495.pdf","created_date":"2025-02-27 09:25:04","last_seen":"2025-02-27 09:25:04","from_file":"2023.057-VWS-WOO-3395155-1032354-PDO.zip","bron":"Z:\\ARCHIEF WOO Documenten\\archieven_files\\2023.057-VWS-WOO-3395155-1032354-PDO.zip","snippet":"1018495\nVERTROUWELLIK\nIndicatiestelling COVID-19 hyperimmuun immuunglobuline alsprofylaxeentherapie bij\nCOVID-19\nAanleiding\nSARS-CoV-2 iseen nieuw infectieus respiratoirvirus. Hoewel deziekte, COVID-1","digest":"0b2a25e763b6"},{"archive_id":"105571","bestandsnaam":"VWS-WOO-08-1018495.pdf","created_date":"2025-02-18 12:18:13","last_seen":"2025-02-18 12:18:13","from_file":"VWS-WOO-3395155-1032354-PDO-d7752f380f706321efde95609910f257ba07e3e396a74008abfad53e0fb845a2.zip","bron":"Z:\\ARCHIEF WOO Documenten\\archieven_files\\VWS-WOO-3395155-1032354-PDO-d7752f380f706321efde95609910f257ba07e3e396a74008abfad53e0fb845a2.zip","snippet":"1018495\nVERTROUWELLIK\nIndicatiestelling COVID-19 hyperimmuun immuunglobuline alsprofylaxeentherapie bij\nCOVID-19\nAanleiding\nSARS-CoV-2 iseen nieuw infectieus respiratoirvirus. Hoewel deziekte, COVID-1","digest":"0b2a25e763b6"},{"archive_id":"80549","bestandsnaam":"VWS-WOO-08-1018495-Indicatiestelling_COVIg_werkgroep_advies_2-12-20.docx.pdf","created_date":"2025-02-18 12:18:07","last_seen":"2025-02-18 12:18:07","from_file":"Besluit__dossier_nr_-d7752f380f706321efde95609910f257ba07e3e396a74008abfad53e0fb845a2.zip","bron":"Z:\\ARCHIEF WOO Documenten\\archieven_files\\Besluit__dossier_nr_-d7752f380f706321efde95609910f257ba07e3e396a74008abfad53e0fb845a2.zip","snippet":"1018495\nVERTROUWELLIK\nIndicatiestelling COVID-19 hyperimmuun immuunglobuline alsprofylaxeentherapie bij\nCOVID-19\nAanleiding\nSARS-CoV-2 iseen nieuw infectieus respiratoirvirus. Hoewel deziekte, COVID-1","digest":"0b2a25e763b6"}],"filename":"Indicatiestelling COVIg werkgroep advies 2-12-20.docx","truncated":false,"elapsed_ms":13}